Back to search results

TVT Registry for Transcatheter Aortic Valve Replacement

This is an observational study, called the STS/ACC Transcatheter Valve Therapy Registry (TVT Registry), that tracks the safety and real-world results of a procedure called Transcatheter Aortic Valve Replacement (TAVR). TAVR is a minimally invasive (less surgery) way to replace a heart valve. The study aims to collect information on people receiving TAVR for Aortic Valve Stenosis (a narrowing of the heart's aortic valve). Researchers will look at major adverse cardiac and cerebrovascular events (serious heart or brain-related problems) 30 days after the procedure. You may be able to join if you are 18 years or older. The study plans to include 16,000 participants. The current recruitment status is unclear.

Study design
This is an observational study designed to track patient safety and outcomes for Transcatheter Aortic Valve Replacement (TAVR). It plans to enroll 16,000 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for major adverse cardiac and cerebrovascular events at 30 days after the procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01737528

STS/ACC Transcatheter Valve Therapy Registry (TVT Registry)

Recruiting
Not specifiedAges 18+Observational
The Society of Thoracic Surgeons
~16,000 participants
Updated 2022-08-25 on ClinicalTrials.gov
What's tested:Transcatheter Aortic Valve Replacement

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Major adverse cardiac and cerebrovascular events
Measured over 30 day

Conditions

Aortic Valve Stenosis

Explore related trials

Aortic Valve Stenosis

Where it's being run

1 sites across 1 states
District of Columbia1

Study leadership

  • John D Carroll, MD · PRINCIPAL_INVESTIGATOR · American College of Cardiology
  • Fred H Edwards, MD · PRINCIPAL_INVESTIGATOR · Society of Thoracic Surgeons

Who to contact

Joan Michaels
[email protected]
(202) 375 6309
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years or older

What this trial measures

  • Major adverse cardiac and cerebrovascular events30 day

    increase in the 30-day risk of adverse events among patients receiving TAVR